|
Orexo's treatment for incontinence/nocturia entering Phase I |
|
|
|
29 Aug 2007 |
Orexo’s product for nocturia and on demand treatment of urinary incontinence, OX 19 has started phase 1 trials
UPPSALA, Sweden | August 29, 2007 |Orexo’s product for nocturia and on demand treatment of urinary incontinence, OX 19 (sublingual desmopressin) has started phase 1 trials. Orexo has developed several formulations and is now proceeding to investigate the lead formulation. The bioavailability trial, which is taking place in Sweden, is expected to be completed by the end of this year. OX 19 exploits Orexo’s novel sublingual tablet technology which enables rapid and reliable onset of action.
About Orexo
Orexo is a pharmaceutical company which focuses on identifying suboptimal therapeutic characteristics of existing products and developing more efficient and effective delivery methods for them. By combining approved active substances with Orexo’s drug delivery technologies it is possible to significantly enhance their therapeutic value, such as providing quicker onset of action or ease of administration. This business model is aimed at bringing products to market faster with lower development risk and costs.
Orexo, which has its global headquarters and development laboratories in Sweden, currently operates across the world through development, licensing and distribution agreements in all major markets.
Orexo has a balanced portfolio with two products on the market, three in registration and/or late stage clinical phase and two under formulation development.
Orexo is listed on the OMX Nordic List Mid Cap (ticker;ORX).
SOURCE: OREXO |
